← Feed

u/Prestigious-Duck-189

2 theses · first seen Sep 4, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d——————
3d——————
1w——————
1m——————
3m——————
6m——————
1y——————

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$SLSr/pennystocksDDbullish
u/Prestigious-Duck-189 · 287d ago1 prior · awaiting results

SLS Part II – Follow-up: from “discounted entry” to early re-rating (and we are still early)

SELLAS is undergoing a structural re-rating driven by clinical trial math, not hype. The Phase 3 REGAL trial is showing prolonged survival indicators (72/80 events with median OS exceeding 13.5 months in a disease with historical 6-8 month survival), while the CDK9 inhibitor SLS009 provides a second value driver. The platform oncology company transition, combined with strong cash position extending to 2027, positions SLS for significant upside as catalysts converge.

At post $5.00Now $10.72+114.4% since postedas of Oct 19, 11:31 AM ET
1d-18.0%
3d-22.8%
1w-17.8%
1m-23.6%
3m-17.4%
6m+199.6%
1y—
original post →
$SLSr/pennystocksDDbullish
u/Prestigious-Duck-189 · 293d ago1 prior · awaiting results

SELLAS Life Sciences (SLS): A Late-Stage Biotech Entering the Final Phase and the Market Is Starting to Notice

SELLAS is a late-stage biotech with a pivotal Phase 3 survival trial (REGAL) nearing completion (72 of 80 events) in a high-unmet-need AML setting, showing constructive safety signals and slowing event rates suggesting better patient survival than modeled. At current sub-$4 share price and $525M market cap, the stock is undervalued relative to probability-weighted outcomes of clinical success and strategic M&A, with a realistic valuation range of $5–12B+ supporting significant upside.

At post $3.31Now $10.72+223.9% since postedas of Oct 19, 11:31 AM ET
1d+13.9%
3d+31.4%
1w+23.9%
1m+17.5%
3m+21.1%
6m+274.3%
1y—
original post →

End of results.